Document Detail

Review of the MitraClip clinical evidence.
MedLine Citation:
PMID:  22322576     Owner:  NLM     Status:  In-Data-Review    
MitraClip system is the only catheter-based device for percutanoeus mitral valve repair available for clinical use, after receipt of the CE Mark in 2008, while it is currently under review for FDA approval in the US. To date, over 3500 MitraClip implants have been performed worldwide, mainly in high risk surgical patients. The aim of this review is to review all the current evidences of the MitraClip therapy in an aim to define its clinical role in the treatment of mitral regurgitation (MR).
F Maisano; M Taramasso; M Cioni; N Buzzatti; P Denti; A Colombo; O Alfieri
Related Documents :
17590726 - Congenital hepatic fibrosis: a study of a saudi family and review.
11489726 - A case of familial clustering of interstitial cystitis and chronic pelvic pain syndrome.
13190436 - Infectious hepatitis; report of an outbreak of 24 cases.
6220956 - A rare phenotype of phosphoglucomutase-2 first detected in mongoloids.
18306556 - A rare spectrum of lesions encountered in fibroid uterus: histopathological report.
8069016 - An autopsy case of light chain deposition disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  60     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  85-94     Citation Subset:  IM    
Cardiothoracic Department, San Raffaele Hospital, Milan, Italy -
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  My rules of a perfect SAPIEN™ transcatheter aortic valve implantation.
Next Document:  Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary interv...